Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Pipeline
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.

Continue
thumbnail

Pulmonary Delivery of PRS-400 Anti-Jagged-1 Anticalin® Proteins Reduce Inflammation-Driven Goblet Cell Metaplasia and Mucus Hypersecretion in Vivo

thumbnail

Preclinical profile of PRS-220, a novel inhaled inhibitor of CTGF/CCN2, in clinical development for Idiopathic Pulmonary Fibrosis

thumbnail

Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma

thumbnail

Development of PRS-400, an inhaled Jagged-1-specific Anticalin® protein for the treatment of muco-obstructive lung diseases. ERS 2022.

thumbnail

PRS-220, a novel inhalable therapeutic intervention for IPF, targeting CTGF directly in the lung. ATS 2022.

thumbnail

The Anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1–dependent manner. AACR 2022.

thumbnail

Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF. ERS 2022.

thumbnail

Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies. AACR 2021.

thumbnail

Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS- 344/S095012, a 4-1BB/PD-L1 bispecific compound for tumor-localized activation of the immune system. AACR 2021.

thumbnail

A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies.ESMO 2020.

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences